https://orcid.org/0000-0001-7978-1652
References
- Palumbo A, Cavallo F, Gay F, et al., Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med. 2014 Sep 4;371(10):895–905.
- Gay F, Oliva S, Petrucci MT, et al., Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. Lancet Oncol. 2015;16(16):1617–1629. doi: 10.1016/S1470-2045(15)00389-7
- Richardson PG, Jacobus SJ, Weller EA, et al., Triplet therapy, transplantation, and maintenance until progression in myeloma. N Engl J Med. 2022 Jul 14;387(2):132–147.
- Attal M, Lauwers-Cances V, Hulin C, et al., Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med. 2017;376(14):1311–1320. doi: 10.1056/NEJMoa1611750
- Perrot A, Lauwers-Cances V, Cazaubiel T, et al., Early versus late autologous stem cell transplant in newly diagnosed multiple myeloma: long-term follow-up analysis of the IFM 2009 Trial. Blood. 2020;136(Supplement 1):39. doi: 10.1182/blood-2020-134538
- Voorhees PM, Kaufman JL, Laubach J, et al., Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood. 2020;136(8):936–945. doi: 10.1182/blood.2020005288
- Moreau P, Attal M, Hulin C, et al., Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet (London, England). 2019;394(10192):29–38. doi: 10.1016/S0140-6736(19)31240-1
- Ruiz-Argüelles GJ, Gómez-Almaguer D. Lessons learned treating patients with multiple myeloma in resource-constrained settings. Curr Hematol Malig Rep. 2021 Feb;16(1):40–44. doi: 10.1007/s11899-021-00616-6
- Gómez-Almaguer D, de Moraes Hungria VT. Multiple myeloma in Latin America. Hematology. 2022 Dec;27(1):928–931. doi: 10.1080/16078454.2022.2112643
- Hong YD, Mullins CD, Onukwugha E, et al., Association of individual low-income status and area deprivation with mortality in multiple myeloma. J Geriatr Oncol. 2023 Mar;14(2):101415.
- Fatoki RA, Koehn K, Kelkar A, et al., Global myeloma trial participation and drug access in the era of novel therapies. JCO Glob Oncol. 2022 Aug;8:e2200119.